Skip to content

CytomX Therapeutics CTMX Depreciation And Amortization Excluding Amortization Of Intangible Assets

Depreciation And Amortization Excluding Amortization Of Intangible Assets at other companies

Grand Canyon Education logo
Grand Canyon EducationLOPE
$8.34M+12.0%
Grand Canyon Education logo
Grand Canyon EducationLOPE
$8.34M+12.0%
Covenant Logistics Group logo
Covenant Logistics GroupCVLG
$23.98M+10.0%
Global Partners logo
Global PartnersGLP
$35.59M-0.9%
Yext logo
YextYEXT
$6.21M-9.4%
Marriott Vacations Worldwide logo
Marriott Vacations WorldwideVAC
$34M-10.5%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets?
CytomX Therapeutics (CTMX) reported depreciation and amortization excluding amortization of intangible assets of $214K in Q1 2026.
How has CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets changed year-over-year?
CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets decreased by 38.7% year-over-year, from $349K to $214K.
What is the long-term trend for CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets?
Over 4 years (2021 to 2025), CytomX Therapeutics's depreciation and amortization excluding amortization of intangible assets has grown at a -16.7% compound annual growth rate (CAGR), from $2.56M to $1.23M.
What does depreciation and amortization excluding amortization of intangible assets mean?
This metric represents the non-cash expense recognized for the wear and tear of tangible fixed assets, excluding the amortization of intangible assets. It reflects the systematic allocation of the cost of physical property, plant, and equipment over their useful lives. Investors use this to understand the capital intensity of the company's operations independent of intangible asset accounting.